Cyprus

Reimbursed Care Access

Cyprus maintains a restrictive statutory regime for classical psychedelics (psilocybin, MDMA, DMT, mescaline, most tryptamines and phenethylamines) with no routine authorised medical use outside clinical research. Ketamine is used clinically (including in research) and esketamine (Spravato) is authorised across the EU — access and public reimbursement in Cyprus is limited and dependent on national formulary / HIO (GeSY) decisions or private-pay arrangements and specialised clinic availability.